Market Trends of China Nuclear Imaging Industry
This section covers the major market trends shaping the China Nuclear Imaging Market according to our research experts:
Neurology Under SPECT Application Segment is Expected to Grow with a Significant CAGR Over the Forecast Period
The market for SPECT applications in neurology is growing due to a variety of factors. The factors that are leading to the growth of this segment include the high burden of neurological and brain disorders and research studies of SPECT Imaging in diagnosing neurological issues. According to the study published by Frontier in Psychiatric in February 2021, in China, the average prevalence of Parkinson's disease (PD) among the Han population is 3.9% of those over 50. By 2030, it is predicted that 4.94 million Chinese people will have PD, making up half of all PD patients worldwide. The high burden of PD disorders is expected to boost the demand for SPECT Imaging that can be used for diagnosis and is expected to boost the market's growth over the forecast period.
Many research studies are being conducted in China on the use of SPECT Imaging. For instance, in March 2021, as per the report published by BMC Neurology, the researchers found that the sensitivity and specificity of the 123I-FP-CIT SPECT scan to clinically diagnose probable dementia with Lewy bodies (DLB) in Chinese memory clinics are 77.7% and 90.4%, respectively. The high specificity and sensitivity are expected to increase the usage of SPECT Imaging across China, leading to its market growth.
Therefore, the above-mentioned growing prevalence of neurological diseases and developments in neurology applications are further expected to drive the growth of the China Nuclear Medicine Market for SPECT Radiopharmaceuticals by Type in this segment.
Oncology Under PET Application Segment is Expected to Have High Growth Over the Forecast Period
Positron Emission Tomography (PET) is a type of Nuclear Medicine procedure that measures the metabolic activity of the cells of body tissues. PET is a combination of Nuclear Medicine and biochemical analysis. It is mostly used to diagnose various types of cancers and is currently used to study cancer phenotyping. For instance, as per the study report published by ACS Journal in April 2022, PET Imaging would further advance cancer evaluation techniques, creating a modality for in vivo cancer phenotyping, as oncology and PET Imaging became increasingly intertwined.
Furthermore, technological advancements and initiatives taken by various manufacturers will also boost the growth of the Chinese Nuclear Imaging market. For instance, in May 2021, United Imaging, a Chinese company involved in Medical Imaging and radiotherapy equipment, launched its uExcel Technology Platform for PET/CT at the China International Medical Equipment Fair (CMEF). The uExcel technology platform includes a range of major hardware and software innovations that provide significant performance enhancements, more powerful imaging capabilities, richer system functionalities, a better user experience, and improved patient safety.
Thus, with new research studies and advancements in PET technology, the China Nuclear Medicine Market for PET Radiopharmaceuticals by Type is expected to witness significant growth, helping to drive the market over the forecast period.
